Fact.MR – A Market Research and Competitive Intelligence Provider: In a recent market analysis, the carbapenem-based antibiotics market would exceed US$ 1.8 billion in 2031.
Ertapenem is Expected to be the Leader in Carbapenem-based Antibiotics Market
The carbapenem-based antibiotics market study offers insights into chief growth drivers and restrains impacting the overall growth trajectory. The report also divulges compelling insights into carbapenem-based antibiotics demand outlook in terms of product, indication, and sales channel. It studies key strategies adopted by vendors to increase sales in carbapenem-based antibiotics market
Fact.MR – A Market Research and Competitive Intelligence Provider: In a recent market analysis, the carbapenem-based antibiotics market would exceed US$ 1.8 billion in 2031. A important market driver will be the rising demand for prophylactic administration of carbapenem-based antibiotics prior to surgery.
The Center for Disease Control and Prevention (CDC) has reported that patients undergoing immunosuppressive treatment are highly susceptible to hospital-acquired pneumonia (HAP). As the cases of hospital acquired pneumonia especially in patients suffering with other chronic diseases like cancer are on the rise, the demand for broad spectrum antibiotics for treatment will increase, thus accelerating the sales of carbapenem-based antibiotics.
As per a report from World Health Organization, the world is facing a shortage of antibiotic resistance bacterial infection treatments. WHO also mentioned that none of 43 antibiotics that are under development are effective enough to address the concerns pertaining to drug resistance in the world’s most dangerous bacteria.
These concerns will drive up demand for generic carbapenem-based antibiotics used to treat conditions like urinary tract infection, bacterial meningitis, and other infections. These generic carbapenem antibiotics are affordable in low-income nations due to their low cost.
Want A Detailed Understanding of Market Functioning? Request for a Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=4425
In the carbapenem-based antibiotics industry, increased investment by carbapenem antibiotic makers to reach lower- and middle-income economies, as well as increased attempts to reinforce supply chains in developed countries, would offer new revenue streams.
“Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.
Key Takeaways:
- The market for carbapenem-based antibiotics is projected to be shaped by larger patient pools and the introduction of novel medications for the treatment of bacterial infections.
- The market for carbapenem-based antibiotics is predicted to develop as the prevalence of bacterial infections rises as a result of prolonged hospital stays and immunocompromising chronic conditions that make patients more susceptible to bacterial infections.
- Ertapenem is now the market leader in carbapenem-based antibiotics.
- Tebipenem is predicted to gain traction in terms of revenue owing to urinary tract infection
- In terms of indication, pneumonia is projected to acquire highest market share as compared to other bacterial infections owing to a large patient pool.
Growth Drivers:
- The demand for carbapenem-based medicines for pneumonia and other infections will rise as the frequency of hospital-acquired bacterial illnesses rises.
- The market will be driven by a high demand for carbapenem-based antibiotics in hospitals prior to surgery.
- With the patent expiration of branded entrapenem and the launch of generic antibiotics, sales of carbapenem-based antibiotics will increase.
Key restraints:
- Stringent regulatory process for drug approval is hampering the sales of carbapenem-based antibiotics.
- Rise in antibiotic resistant bacterial strains and tedious procedure for developing new carbapenem based antibiotics will hamper the market growth.
To learn more about Carbapenem-based Antibiotics Market, you can get in touch with our Analyst at:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=4425
Competitive Landscape
Top Manufacturers of carbapenem-based antibiotics are Pfizer Inc., Merck Co. & Inc. and Sumitomo Dainippon Pharma Co., Ltd. They collectively account for 9 out of 10 sales of carbapenem-based antibiotics across the globe.
As these generic carbapenem-based antibiotics are highly effective in treating range of bacterial infections, prominent market players are emphasizing on increase supply of these antibiotics in different countries to enhance their global outreach.
In May 2021, Dr. Reddy’s Laboratories Ltd. launched a generic entrapenem for injections in 1 g per vial packaging. Ertapenem is a type of carbapenem-based antibiotics used in treatment of gram negative bacterial infections.
In February 2019, Frazier Healthcare Partners launched a new biopharmaceutical company Recida Therapeutics, Inc. which specializes in developing novel therapeutics for serious antibiotic-resistant infections. Recida is working towards devising carbapenem-based antibiotics for treatment of multidrug-resistant gram-negative infections
Key players operating in the carbapenem-based antibiotics market are
- Amedica Corporation
- Cam Carbapenem-based antibiotics BV
- CeramTec GmbH
- Compagnie de Saint-Gobain
- CoorsTek Medical LLC
- DePuySynthes
- DOCERAM Medical Ceramics GmbH
- H.C. Starck GmbH
- Morgan Advanced Materials Plc.
- Royal DSM NV
More Insights on the Carbapenem-based Antibiotics Market:
Fact.MR provides an unbiased analysis of the carbapenem-based antibiotics market, presenting historical demand data (2019-2029) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global carbapenem-based antibiotics market with a detailed segmentation on the basis of:
Product Type
- Meropenem
- Ertapenem
- Imipenem
- Doripenem
- Panipenem
- Tebipenem
Indication
- Intra-abdominal Infections
- Urinary Tract Infections
- Pneumonia
- Bacterial Meningitis
- Skin and Skin Structure Infections
- Acute Pelvic Infections
- Prophylaxis of Surgical Site Infection
- Respiratory Tract Infections
- Gynaecologic Infections
- Endocarditis
- Others
Sales Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Key Questions Covered In the Carbapenem-Based Antibiotics Market Report
- The report offers insight into carbapenem-based antibiotics demand outlook for 2021-2031
- The market study also highlights projected sales growth for carbapenem-based antibiotics market between 2021 and 2031
- Carbapenem-based antibiotics market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Carbapenem-based antibiotics market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain -
Generic Injectables Market Forecast - The global generic injectables industry is expected to grow rapidly. The market is expected to grow due to the expiration of patents on blockbuster injectable molecules, research and development of large molecule generic injectable, and a robust product pipeline.
Extended Oral Antibiotics Market Trends - Increased number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections, extended oral antibiotics are expected to have significant demand in the market. Furthermore, increased R&D investments is boosting the global extended antibiotics market.
Anticancer Drugs Market Analysis - Anticancer drug sales are increasing as a huge number of awareness initiatives are launched by governments and central authorities around the world. The development of treatments with better patient outcomes and fewer side effects than traditional ones is expected to improve patients’ trust in these drugs, bolstering the anticancer drug market’s growth prospects.
Antibiotic-Associated Diarrhea Treatment Market Scope - The market for antibiotic-associated diarrhea therapy has grown as a result of the availability of over-the-counter medications, which has contributed to an increase in the prevalence of antibiotic-associated diarrhea.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR